Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma 3Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Teratoma, Ovarian 1Struma Ovarii 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Myelodysplastic Syndromes 1Metabolic Syndrome 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hemangioma, Cavernous, Central Nervous System 1Glioblastoma 1Genetic Predisposition to Disease 1Disease 1Diabetes Mellitus 1Cytopenia 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

Propranolol 2daratumumab 1Watchful Waiting 1Surgical Procedures, Operative 1Simvastatin 1Observation 1DNA 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangioma, Cavernous, Central Nervous System × DNA × Clear all
NCT03474614 2024-04-19

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

St. Joseph's Hospital and Medical Center, Phoenix

Phase 2 Terminated
4 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡